We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Horizon Discovery Group Plc | LSE:HZD | London | Ordinary Share | GB00BK8FL363 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 184.50 | 184.50 | 185.00 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
28/1/2016 10:25 | They are and have been very busy if you go through these pages: | mirandaj | |
28/1/2016 09:10 | Double bottom again on the chart - that looks very similar to the bottom back in 2014 before it rallied hard. | phowdo | |
28/1/2016 08:39 | Up at the off is usually a good sign - someone looking for stock.....? | deltrotter | |
28/1/2016 08:37 | Hopefully; it's my outsider in stockchallenge. | cestnous | |
27/1/2016 16:39 | Just thinking that cestnous. Seller cleared by the insti's? | deltrotter | |
27/1/2016 16:23 | Bottoming at last? | cestnous | |
22/1/2016 15:24 | Some stock around, can buy at 127.5199 currently. | martincc | |
22/1/2016 14:08 | Cumbrian, well done marra. Keep buying. | deltrotter | |
22/1/2016 13:55 | Most posts in a day for months and all the positive talk has caused a rare tick up! | cumbrian2 | |
22/1/2016 13:37 | Invesco have gone over 12% | nurdin | |
22/1/2016 13:34 | Good post AB - I totally agree with your sentiment. I hold from much higher up - average 190p. Also steadily add more and will continue to. The price in 5 years time is what is important to me.... | deltrotter | |
22/1/2016 13:09 | This is definitely a sleeper, but one with enormous potential. Gene editing using the CRISPR-Cas9 technique is a growing field, and is now taking place on humans too. So far only in non-heritable areas, but that will change too. It won't be long before germ line gene editing gets sanctioned, and when it does - and even before it does - HZD will be a beneficiary, in a major financial way. This is cutting edge bio-technology, with such potential that I hesitate to put any numbers on it. But, subject to the company being properly managed and run, it must surely be a very profitable investment over the next few years. Buying/adding at current price levels is, IMHO, a no-brainer. I'm already long. | andrewbaker | |
19/1/2016 08:47 | hopefully a re-rating will be seen this year!!! | pjj71 | |
19/1/2016 06:58 | "Personalised medicines standard bearer, Horizon Discovery, wowed the UK market with a transformational trading update flagging up a revenues surge, an R & D milestone treasure chest and the promise of more to come." Panmure Gordon Analyst Reaffirmed 'buy' with £2.70 target. CFO 'extremely happy': "Demand for life science group Horizon Discovery's (LON:HZD) products is strong and it expects to report 120% growth in revenue in this side of the business for the year to end December. Speaking to Proactive, chief finance officer Richard Vellacott said: “The commercial drivers of our business are firing on all cylinders.” He said product growth, partnerships and the potential to leverage should create a domino effect, allowing the firm to continue growth rapidly moving forward." The trading update here: | mirandaj | |
18/1/2016 19:51 | Good update and no movement on price? Negative one wouldhave seen it hammered. | jugu | |
18/1/2016 08:04 | Nice announcement. Glad I hung on in. | cestnous | |
18/12/2015 08:22 | still hopeful!!! | pjj71 | |
26/11/2015 13:22 | hopefully a rebound to 200p and beyond coming soon.. | pjj71 | |
25/11/2015 20:11 | Horizon Discovery says personalised medicine market is 'exploding' | deltrotter | |
23/11/2015 08:32 | still no holding updates!! | pjj71 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions